The M2 module of the cys-his-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway

Journal of Biological Chemistry

Volumn 287, Issue 52, 2012, Pages 43492-43501

  Saavedra, Yascara Grisel Luna ^a   Day, Robert ^b   Seidah, Nabil G ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL MEMBRANES; CYTOLOGY; PROTEINS;

CELLULAR DEGRADATION; CELLULAR EXPRESSION; DEGRADATION PATHWAYS; DEGRADING ACTIVITIES; EXTRACELLULAR ACTIVITY; INTRACELLULAR PATHWAYS; LOW DENSITY LIPOPROTEIN RECEPTORS; MULTIDOMAIN PROTEINS;

MOLECULAR BIOLOGY;

LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYSTEINE HISTIDINE RICH DOMAIN; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION;

EID: 84871558716     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.394023     Document Type: Article

References (42)

1. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1). Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933 (Pubitemid 36183932)
2. Seidah, N. G., and Prat, A. (2012) The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367-383
3. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (Pubitemid 36666925)
4. Marduel, M., Ouguerram, K., Serre, V., Bonnefont-Rousselot, D., Marques-Pinheiro, A., Berge, K. E., Devillers, M., Luc, G., Lecerf, J. M., Tosolini, L., Erlich, D., Peloso, G. M., Stitziel, N., Nitchke, P., Jais, J. P., Abifadel, M., Kathiresan, S., Leren, T. P., Rabes, J. P., Boileau, C., and Varret, M. (2012) Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum. Mutat., doi: 10.1002/humu.22215
5. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chretien, M., Prat, A., and Seidah, N. G. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865-48875 (Pubitemid 39625767)
6. Naureckiene, S., Ma, L., Sreekumar, K., Purandare, U., Lo, C. F., Huang, Y., Chiang, L. W., Grenier, J. M., Ozenberger, B. A., Jacobsen, J. S., Kennedy, J. D., DiStefano, P. S., Wood, A., and Bingham, B. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 420, 55-67 (Pubitemid 37393374)
7. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., Warren, L. C., Xia, D., and Qiu, X. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419 (Pubitemid 46685885)
8. Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., and Walker, N. P. (2007) The crystal structure of PCSK9. A regulator of plasma LDL-cholesterol. Structure 15, 545-552 (Pubitemid 46702689)
9. Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., and Spraggon, G. (2007) The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 104, 14604-14609 (Pubitemid 350003191)
10. Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N. G., and Davignon, J. (2010) A new method for measurement of total plasma PCSK9. Clinical applications. J. Lipid Res. 51, 140-149
11. Maxwell, K. N., and Breslow, J. L. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U.S.A. 101, 7100-7105 (Pubitemid 38596449)
12. Park, S. W., Moon, Y. A., and Horton, J. D. (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279, 50630-50638
13. Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732 (Pubitemid 46785153)
14. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M. C., Day, R., Duclos, F. J., Witmer, M., Parker, R., Prat, A., and Seidah, N. G. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation. Evidence for an intracellular route. J. Biol. Chem. 284, 28856-28864
15. Holla, Ø. L., Cameron, J., Berge, K. E., Ranheim, T., and Leren, T. P. (2007) Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol. 8, 9
16. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612 (Pubitemid 47100234)
17. Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. U.S.A. 105, 1820-1825 (Pubitemid 351439423)
18. Lo Surdo, P., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., and Carfí, A. (2011) Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12, 1300-1305
19. McNutt, M. C., Lagace, T. A., and Horton, J. D. (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282, 20799-20803 (Pubitemid 47099894)
20. Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363-2372
21. Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2009) PCSK9. A convertase that coordinates LDL catabolism. J. Lipid Res. 50, S172-S177
22. Seidah, N. G. (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets 13, 19-28
23. Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y. A., and Horton, J. D. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc. Natl. Acad. Sci. U.S.A. 102, 5374-5379 (Pubitemid 40530265)
24. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., Seidah, N. G., and Prat, A. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9). Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48, 646-654
25. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr., and Hobbs, H. H. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272
26. Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah N.G., and Prat A (2012) Gene inactivation of PCSK9 reduces atherosclerosis in mice. Circulation 125, 894-901
27. Davignon, J., Dubuc, G., and Seidah, N. G. (2010) The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr. Atheroscler. Rep. 12, 308-315
28. Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., and Pordy, R. (2012) Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy. A phase 2 randomised controlled trial. Lancet 380, 29-36
29. Zhang, D. W., Garuti, R., Tang, W. J., Cohen, J. C., and Hobbs, H. H. (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 13045-13050
30. Strøm, T. B., Holla, Ø. L., Tveten, K., Cameron, J., Berge, K. E., and Leren, T. P. (2010) Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain. Mol. Genet. Metab. 101, 76-80
31. Benjannet, S., Saavedra, Y. G., Hamelin, J., Asselin, M. C., Essalmani, R., Pasquato, A., Lemaire, P., Duke, G., Miao, B., Duclos, F., Parker, R., Mayer, G., and Seidah, N. G. (2010) Effects of the prosegment and pH on the activity of PCSK9. Evidence for additional processing events. J. Biol. Chem. 285, 40965-40978
32. Holla, Ø. L., Laerdahl, J. K., Strøm, T. B., Tveten, K., Cameron, J., Berge, K. E., and Leren, T. P. (2011) Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor. Biochem. Biophys. Res. Commun. 406, 234-238
33. Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., and Leren, T. P. (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15, 1551-1558
34. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., and Seidah, N. G. (2006) The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A. Functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281, 30561-30572 (Pubitemid 44582112)
35. Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., and Prat, A. (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J. Biol. Chem. 286, 4257-4263
36. Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., and Hobbs, H. H. (2006) A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410-422 (Pubitemid 43291224)
37. Davignon, J., and Dufour, R. (2007) Primary Hyperlipidemias: An Atlas of Investigation and Diagnosis, pp. 1-128, Clinical Publishing, Oxford
38. Sikka, P., Kapoor, S., Bindra, V. K., Sharma, M., Vishwakarma, P., and Saxena, K. K. (2011) Statin intolerance. Now a solved problem. J. Postgrad. Med. 57, 321-328
39. Cariou, B., Le May, C., and Costet, P. (2011) Clinical aspects of PCSK9. Atherosclerosis 216, 258-265
40. Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., Santoro, J. C., Ehrhardt, A., Lewis, D., Fisher, T. S., Ha, S., Njimoluh, L., Wood, D. D., Hammond, H. A., Wisniewski, D., Volpari, C., Noto, A., Lo Surdo, P., Hubbard, B., Carfí, A., and Sitlani, A. (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285, 12882-12891
41. Holla, Ø. L., Cameron, J., Tveten, K., Strøm, T. B., Berge, K. E., Laerdahl, J. K., and Leren, T. P. (2011) Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J. Lipid Res. 52, 1787-1794
42. Du, F., Hui, Y., Zhang, M., Linton, M. F., Fazio, S., and Fan, D. (2011) Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J. Biol. Chem. 286, 43054-43061